Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
20 April 2021Portfolio NewsMestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer- 15 April 2021Portfolio NewsSutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
15 April 2021Portfolio NewsSitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
12 April 2021Portfolio NewsXilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
7 April 2021Portfolio NewsArtios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
7 April 2021SV NewsThe Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio- 3 April 2021SV NewsUK vaccine supremo Kate Bingham: ‘The bickering needs to stop’
- 30 March 2021Portfolio NewsPionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
22 March 2021Portfolio NewsEvidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform
18 March 2021Portfolio NewsWellspring Capital Management Recapitalizes HealthPRO Heritage- 17 March 2021Portfolio NewsAmathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases
